Segregation in the Design of Gene Therapy Manufacturing Facilities by Peter Walters

Segregation in the Design of Gene Therapy Manufacturing Facilities by Peter Walters
Posted: Nov 09 2017
A number of gene therapies are in late-stage clinical trials and expected to reach the market in the next several years. Unlike traditional biologic drugs, gene therapy production can involve the manipulation of replication of viruses.

Segregation of manufacturing operations involving viruses is a crucial consideration when designing processes and overall facilities. Read the full article by CRB's Peter Walters here!

Search News